Latest news in endocrinology

Among the top stories in endocrinology from the Endocrine Annual Society Meeting is the possibility of house calls returning via virtual visits, with an expert discussing the benefits and challenges of telemedicine for diabetes. According to findings from the E-LIFT trial presented at the meeting, the oral SGLT2 inhibitor empagliflozin may benefit patients with type 2 diabetes and nonalcoholic fatty liver disease by aiding in the reduction of liver fat.

Other stories include daily injections of the GLP-1 receptor agonist semaglutide producing weight loss in adults with obesity who did not have diabetes, measuring heat rate variability via a wearable biosensor could alert patients with type 1 diabetes to a hypoglycemic episode, and young patients with type 1 diabetes who used an artificial pancreas system for 3 months experienced a reduction in HbA1c and an improvement in time to glucose values. – by Jake Scott

Telemedicine poised to replace in-person visits, improve patient outcomes in diabetes

Telemedicine offers advantages for patients and providers in diabetes management, including opportunities to reach more patients at reduced cost, but researchers must take steps to ensure important metrics are considered so the best methods are utilized, according to a speaker. Read More.

Empagliflozin reduces liver fat in patients with type 2 diabetes, NAFLD

Empagliflozin, an oral SGLT2 inhibitor, may provide substantial benefit to patients with type 2 diabetes and nonalcoholic fatty liver disease by aiding in the reduction of liver fat, according to findings from the E-LIFT trial. Read More.

Semaglutide produces weight loss in adults with obesity who do not have diabetes

Nearly two-thirds of adults with obesity and without diabetes who received daily injections of the GLP-1 receptor agonist semaglutide decreased their body weight by at least 10% compared with about one-third of those taking liraglutide, according to results of a phase 2 study. Read More.

Heart rate variability via smart sensor may predict hypoglycemia in type 1 diabetes

Continuous measurement of heart rate variability via a wearable biosensor could predictively alert patients with type 1 diabetes to a hypoglycemic episode, according to data from a proof-of-principle study. Read More.

Artificial pancreas safe, effective in young children with type 1 diabetes

Children aged 7 to 13 years with type 1 diabetes who used an artificial pancreas system for 3 months experienced a reduction in HbA1c and an improvement in time to glucose values in the target range, without any episodes of severe hypoglycemia or diabetic ketoacidosis, according to study data. Read More.

PAGE BREAK